Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 12;22(2):14.
doi: 10.1007/s11864-020-00807-y.

A Review of Pharmacologic Management in the Treatment of Mesothelioma

Eric P Borrelli  1 , Conor G McGladrigan  2
Affiliations
Review

A Review of Pharmacologic Management in the Treatment of Mesothelioma

Eric P Borrelli et al. Curr Treat Options Oncol. .

Abstract

Mesothelioma is a rare and severe form of cancer that is associated with asbestos exposure. Approximately 2500 Americans die annually from this condition with a median survival of 1 year. The latency period of this disease ranges anywhere from 20 to 70 years, with shorter latency periods associated with a higher exposure intensity to asbestos. Therefore, cases of mesothelioma are expected in the coming decades. This highlights the need for clinicians to understand the pharmacologic regimens available for treating this rare, yet serious malignancy. With multiple treatment regimens available in the treatment of this condition, clinicians should take an evidence-based approach and consider the totality of evidence and safety information while considering the best patient-centered approach for treatment. This article provides a review of current pharmacologic treatment options available for mesothelioma and goes into detail about the recommended medication regimens and dosages and the available evidence of efficacy, effectiveness, and/or safety and estimates the annual cost of treatment for these medications on the U.S. healthcare system per patient. A brief introduction is provided for several promising agents currently under investigation for mesothelioma as well.

Keywords: Asbestos; Cost; Mesothelioma; Pharmaceuticals; Treatment guidelines.

PubMed Disclaimer

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28–38. - PubMed - PMC
    1. Baldwin CA, Beaulieu HJ, Buchan RM, Johnson HH. Asbestos in Colorado schools. Public Health Rep. 1982;97(4):325–31. - PubMed - PMC
    1. Corn M, Crump K, Farrar DB, Lee RJ, McFee DR. Airborne concentrations of asbestos in 71 school buildings. Regul Toxicol Pharmacol. 1991;13(1):99–114. - PubMed
    1. Irving KF, Alexander RG, Bavley H. Asbestos exposures in Massachusetts public schools. Am Ind Hyg Assoc J. 1980;41(4):270–6. - PubMed
    1. Sprince NL, Oliver LC, McLoud TC. Asbestos-related disease in plumbers and pipefitters employed in building construction. J Occup Med. 1985;27(10):771–5. - PubMed

MeSH terms

LinkOut - more resources